Status: Recruiting
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Participants needed: 64
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sonya ReidUpdated: Jan 20, 2026Locations: 3
Eligibility criteria
Signed and dated written informed consent. [+16]
Prior chemotherapy in the metastatic setting [+3]